Anti-acne medication Tretinoin (Retin-A, Renova) for sale
How and where to order Retin-A, Renova (Tretinoin) 0.025%, 0.05%, 0.1% 20 g gel and cream online:
from $8.83 per tube 20 g
5% discount coupon: 5OFF
from $8.90 per tube 20 g
Cream and Gel
10% discount coupon: hf-5478
DRUGS FOR HEALTH
from $9.39 per tube 20 g
Gel and Cream
5% discount coupon: A1XKPKC
RETIN-A (TRETINOIN) CREAM, GEL, LIQUID: USE IN SPECIAL POPULATIONS (see "References")
Pregnancy Category C
Oral tretinoin has been shown to be teratogenic in rats, mice, hamsters, and subhuman primates. It was teratogenic and fetotoxic in Wistar rats when given orally or topically in doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). However, variations in teratogenic doses among various strains of rats have been reported. In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than the other species examined, fetal malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human systemic does adjusted for total body surface area), although increased skeletal variations were observed at all doses. A dose-related increase in embryolethality and abortion was reported. Similar results have also been reported in pigtail macaques.
Topical Tretinoin (Retin-A) gel, cream, and liquid in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Anomalies (humerus: short 13%, bent 6%, os parietal incompletely ossified 14%) have also been reported when 10 mg/kg/day was topically applied.
There are other reports in New Zealand White rabbits administered doses of greater than 0.2 mg/kg/day (3.3 times the maximum human systemic dose adjusted for total body surface area) of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.
In contrast, several well-controlled animals studies have shown that dermally applied tretinoin may be fetoxic, but not overly teratogenic in rats and rabbits at doses of 1.0 and 0.5 mg/kg/day, respectively (8 times the maximum human systemic does adjusted for total body surface area in both species).
With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone. Thirty human cases of temporally associated congenital malformations have been reported during two decades of clinical use of Retin-A (Tretinoin). Although no definite pattern of teratogenicity and no causal association has been established from these cases, five of the reports describe the rare birth defect category holoprosencephaly (defects associated with incomplete midline development of the forebrain). The significance of these spontaneous reports in terms of risk to the fetus is not known.
Topical tretinoin has been shown to be fetotoxic in rabbits when administered 0.5 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased intrauterine death in rats when administered 2.5 mg/kg/day (20 times the maximum human systemic dose adjusted for total body surface area).
There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Retin-A is administered to a nursing woman.
Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Safety and effectiveness in a geriatric population have not been established. Clinical studies of Retin-A (Tretinoin) cream, gel and liquid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
Retin-A (Tretinoin) related pharmaceutical drugs and medications
|Trade name of the drug
||Pharmaceutical forms and doses
|Accutane use in specific populations
||Capsules; Oral; Isotretinoin 10 mgCapsules; Oral; Isotretinoin 20 mg
Retin-A prescribing information
Disclaimer: Please note, this website is not an online pharmacy, drugstore and related online pharma shop. It does not sell, supply or advertise any prescription and OTC drugs, medications, other goods and services. All reviews, links, lists, databases, texts, and other content on the website are provided free and only for informational and educational purposes. Medical content on this website, including drug names, indications, contraindication, side effects, categories, classifications, forms, doses, prices, other health and pharmaceutical information are taken only from trusted and authoritative professional sources (see "References"), reviewed and prepared by our licensed experts, content inspectors and editors.
You should always consult your doctor or other healthcare professional before using any medication. This website, our staff and support do not provide own medical instructions and advices.
All brands and trade names appearing on the website are registered trademarks of their respective companies.
Remember that buying drugs and medicines online is a responsibility only of customers, sellers and suppliers regarding existing legislation in their jurisdictions.
Share us in social media:
Copyright © 2014-2019 TretinoinBuyOnline.com, a division of Pharma-Doctor.com pharmaceutical network. All rights reserved.
Home Page |
Cookies Policy |
Terms of Service |